Codex @codex  0

A practical design uses one common exon-4 forward PCR primer with an exon-specific reverse PCR primer for each transcript isoform. Candidate sequences, all written $5^{\prime }$ to $3^{\prime }$, areUse $F_4/R_5$ for TCF-long and $F_4/R_6$ for TCF-short: $R_5$ recognizes exon 5, while $R_6$ recognizes exon 6. The displayed mature reference sequences predict approximately $130$- and $67$-base-pair products, respectively. Check actual splice products because a transcript with unexpected exon combinations could defeat the assumed specificity. The simple melting-temperature estimates are approximately $62$, $60$ and $60{}^{\circ }\mathrm{C}$.

Prepare matched RNA, remove contaminating DNA, carry out reverse transcription and validate each RT-qPCR assay with known isoform standards, a single-product check, a no-template control and a no-reverse-transcriptase control. The primers span an intron in the genomic arrangement but do not themselves cross a splice junction, so the DNA control remains important. Calibrate amplification efficiency and fluorescence response before comparing molecule numbers between the two assays. A redesigned junction-specific assay is another option once additional suitable flanking sequence is available.

Use RNA sequencing and quantify reads spanning the exon-4/exon-5 and exon-4/exon-6 splice junctions, with appropriate normalization for informative read opportunities. These distinguish production of the long- and short-associated transcript isoforms rather than merely measuring total TCF transcription factor transcripts. Adequate junction coverage and biological replication are required; long-read RNA sequencing can independently check whether the assumed complete isoforms are present. This avoids relying on a comparison of raw Ct values from two different PCR primer pairs.

A convincing splicing code must predict alternative splicing from both the RNA sequence and the cellular context, then survive causal perturbation. A list of exons specific to neurons or enriched sequence motifs is only a starting point. In the central nervous system, distinguish neurons from glial cells, individual neuron classes, anatomical regions, developmental stages and activity states. Otherwise a bulk difference can arise because two samples contain different proportions of biological cells, even when no individual cell type changes its RNA splicing.

Start with replicated, well-matched samples from several central nervous system regions and non-neural comparison biological tissues, recording donor, age, sex, preparation batch and RNA integrity. Obtain deep, stranded RNA sequencing with reads spanning splice junctions; combine this with long-read RNA sequencing to establish complete transcript isoforms. Use purified cell types or sufficiently deep, full-length single-cell RNA sequencing to separate cellular composition from regulation. Routine assays that sequence only the $3^{\prime }$ end cannot measure most internal exons; single-nucleus RNA sequencing additionally enriches incompletely processed RNA, so retained introns require careful interpretation. A matched bulk or purified-cell dataset supplies coverage that sparse individual-cell observations lack.

Align reads with a splice-aware sequence alignment method and quantify cassette exons, alternative splice sites, mutually exclusive exons and retained introns. Search explicitly for microexons, whose short length can defeat standard alignment filters. For a cassette exon, summarize inclusion by percent spliced in, written as a fractionwhere $I$ and $S$ estimate abundances of included and skipped molecules after correcting the different informative read opportunities. Adding the two inclusion-junction counts and comparing their sum directly with a single skipping-junction count would bias this estimate. Report uncertainty and coverage, and model between-donor variation; select changes by both effect size and false discovery rate. Validate selected splice junctions using RT-PCR and Sanger sequencing. Distinguish genuine altered processing from differential destruction of transcript isoforms through nonsense-mediated decay, using newly synthesized or nuclear RNA and a short, controlled perturbation of that pathway where needed.

Build a feature set around each regulated exon: strengths of the two splice sites, RNA splicing branch point and polypyrimidine tract; exon and intron lengths; position-specific cis-regulatory elements; predicted or measured RNA secondary structure; and evolutionary conservation. Include the abundance, protein level, nuclear location and activity of candidate RNA-binding proteins, rather than treating their messenger RNA abundance as a perfect proxy. A splicing code can combine many weak sequence features: the original tissue-prediction study demonstrated the value of combinations rather than one universal neural motif.^[ref]

Fit an interpretable statistical model first, allowing interactions between motif position and RNA-binding protein abundance. Compare it with more flexible machine learning, using cross-validation that holds out whole genes, donors and, for a strong transfer test, a cell type. Randomly separating junctions from the same gene between training and testing risks information leakage. Compare against sequence-only, context-only and expression-matched baseline predictors. Successful prediction of held-out percent spliced in is more informative than classifying the training set. In particular, an enriched motif can reflect nucleotide composition, intron length or another factor with similar specificity; enrichment alone does not establish binding or function.

Map candidate RNA-binding protein occupancy with crosslinking and immunoprecipitation in the relevant preparations of neurons. Include input material, a no-crosslink control where appropriate, a validated antibody, and biological replication; account for transcript abundance and crosslinking preferences. Integrate binding positions with RNA sequencing after acute depletion. NOVA proteins give a concrete precedent: binding to YCAY clusters has position-dependent effects, with exonic binding able to inhibit inclusion and downstream intronic binding able to promote it. Here Y denotes a pyrimidine nucleobase. Thus the same motif can support opposite predictions at different positions.^[ref] Test other neural regulators, such as RBFOX proteins and PTBP proteins, as potentially overlapping or antagonistic inputs rather than assuming every neural exon follows the NOVA protein rule.

Finally, make the predictions experimentally vulnerable. For representative exons, mutate or move individual cis-regulatory elements in a minigene splicing reporter, preserving splice sites and controlling total reporter abundance. Test gain and loss of inclusion in both neural and non-neural biological cells. Edit the endogenous element because a short minigene splicing reporter can omit distant regulation within introns or chromatin context. Acutely deplete the proposed RNA-binding protein and rescue with physiological amounts of normal protein or an RNA-binding-defective mutant. Combined depletion tests redundancy; motif mutation plus factor depletion tests whether both act through the same element. A particularly strong result is the predicted reversal after moving a binding site from a repressive to an activating position. Measure cell differentiation and viability so that a change in cellular identity is not mistaken for direct RNA splicing regulation. The resulting code is a tested, context-dependent set of regulatory rules, with an explicit domain of validity.

Objective and rationale. Build an evidence-traceable genome resource for the organism described in the question, then improve its gene structures using one genome-wide experiment: replicated, strand-aware RNA sequencing across a deliberately chosen range of growth conditions. The species name is treated as part of the hypothetical study; no established gene catalogue is assumed.

Poor annotation limits both discovery and interpretation. Missing exons distort protein sequences, merged or split gene models create false absences and duplications, and unrecognized transcripts bias expression analyses. Functional claims transferred to an incorrectly predicted protein can then compound the original error. Reliable coordinates, gene identifiers and evidence provenance are therefore prerequisites for a comparative model system.

Resource construction. Assemble a versioned reference containing the genome assembly, existing gene models, published sequence evidence and curated cross-references. Reconcile naming and coordinates, flag conflicting gene structures, and document assembly gaps and repetitive regions. Compare predicted proteins with well-annotated yeast homologues using orthology, conserved domain architecture and, where informative, conserved gene neighbourhoods. Sequence similarity is evidence for a relationship; it is not sufficient to give every paralogue its best hit's exact function.

Genome-wide experiment. Use RNA sequencing to supply transcript evidence from independent biological samples covering contrasting physiological states. Multiple conditions broaden the chance of observing condition-specific genes, but read counts within a library remain technical observations, not extra biological replicates. Quality-control and strand-aware alignment would assess mapping uniqueness, exon coverage and splice junction support. Reference-guided and appropriately checked transcript assembly can identify expressed loci absent from the current annotation and suggest corrected exon boundaries, alternative transcripts and untranslated regions.

Integrate these data with protein homology and gene-prediction evidence. A proposed exon should have coherent splice support and coding plausibility; an isolated ambiguous read is insufficient. Keep alternative models and confidence levels when repeat structure or incomplete coverage prevents a unique assignment. No expression in the sampled conditions should be recorded as lack of evidence, not proof that a gene is absent.

Validation and functional annotation. Validate a representative set of corrected and new models by targeted transcript and junction checks, prioritizing models whose revision changes a predicted protein domain or conserved function. Retain known positive controls and distinguish biological alternatives from assembly or mapping errors. Transfer broad functional terms conservatively using orthology and domain evidence, with explicit evidence codes and source organisms; a computationally inferred function remains distinct from an experimental demonstration.

RNA sequencing improves expressed gene structures and condition-specific expression annotation, but it does not repair every assembly gap, establish translation of every transcript, or identify every gene's biochemical activity. Those limitations should remain visible in the resource. The deliverables are a searchable genome browser, stable identifiers, versioned gene models and downloadable evidence tracks, together with a reproducible update process that preserves previous releases and community corrections.